Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
ENDRA Life Sciences Inc(NDRA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NDRA
11/11/2026: NDRA (1-star) is currently NOT-A-BUY. Pass it for now.
ENDRA Life Sciences Inc is a clinical-stage medical technology company developing its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) platform for tissue characterization. Its primary focus is creating a non-invasive, cost-effective tool to diagnose liver diseases, which represents a significant market opportunity. However, the company faces high risks, including the absence of established recurring revenue, ongoing operating losses, and significant regulatory hurdles before commercial success can be achieved. It is best suited for speculative investors with a high risk tolerance who are focused on long-term clinical development milestones. Investors should closely monitor upcoming FDA regulatory updates and clinical trial results as these are primary catalysts for the company.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on its technology, but lacks the established growth metrics typical of mature investments. |
| Momentum investor | Mixed fit | Momentum suitability is conditional on positive clinical or regulatory signals triggering significant price appreciation. |
| Value investor | Weak fit | The company does not have the earnings or cash flow history required for traditional value investing. |
| Dividend investor | Weak fit | The company is in an R&D phase and does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and early-stage nature of the firm make it unsuitable for conservative, risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Speculative nature and low market capitalization contribute to significant price swings. |
| Valuation risk | High | Difficulty in valuing early-stage pre-revenue firms often leads to potential price corrections. |
| Competition risk (Major MedTech incumbents) | High | Competition from large, entrenched diagnostic imaging players limits market access. |
| Business quality | Medium | The business relies entirely on the successful commercialization of a single platform technology. |
| Dividend income | Low / none | There is no expectation of dividend income as the company burns cash to fund operations. |
| Execution risk | High | The company must navigate complex regulatory environments to bring its primary product to market. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -65.4% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.15M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 12.7K shares | Beta -0.11 | 52 Weeks Range 2.96 - 6.95 | Updated Date 11/11/2026 |
52 Weeks Range 2.96 - 6.95 | Updated Date 11/11/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.26 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| TAEUS Platform Sales | Anticipated future revenue from the sale of diagnostic systems and associated licensing or service fees. | The company currently does not generate significant revenue; its financial future depends entirely on successful product approval and sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5.95M | Price to Sales(TTM) 1838.78 |
Enterprise Value 5.95M | Price to Sales(TTM) 1838.78 | ||
Enterprise Value to Revenue 1845.91 | Enterprise Value to EBITDA -0.11 | Shares Outstanding 1.50M | Shares Floating 1.36M |
Shares Outstanding 1.50M | Shares Floating 1.36M | ||
Percent Insiders 18.03 | Percent Institutions 18.13 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.